24KIT
On REFLECTion
New data from studies on the use of Abbott's
FreeStylel Libre sensor show improved results for
T1s and T2s.
Abbott results from its
REFLECT real world
studies that show the
use of FreeStyle Libre
(FSL) continuous glucose monitoring
(CGM) technology is associated
with a significant reduction in the
risk of hospitalization for heart
complications in people with
diabetes. For the first time, data
showed that CGM technology
can help lessen the severity of
cardiovascular complications -
regardless of a prior history of
low blood sugar events or heart
disease-related hospitalizations - in
individuals with Type 1 diabetes.
Findings from the studies also show
a similar reduction in heart-related
hospitalizations for those with Type
2 diabetes on insulin using Libre
technology.
For people with diabetes, the
REFLECT findings suggest that the
use of Libre technology could also
potentially lead to lower healthcare
costs due to the reduction in
hospital admissions related to heart
complications.
David Nathanson, MD, PhD,
Karolinska University Hospital in
Sweden, one of the lead authors
of the studies, says, "These results
are remarkable, as we see dual
benefits from CGM technology in
managing diabetes and its associated
cardiovascular complications. CGMs
empower people to proactively
manage their diabetes and make
informed health choices through
real-time, constant feedback on
their glucose levels. This data shows
that using CGMs is linked with
significantly reduced hospitalizations
related to heart issues, which can